Though most biopharma investment is in two states, follow this model to bring the research—and investments—elsewhere.
The NIH says funding cuts would save it billions of dollars a year. D.C.-area industry and academic leaders say it would cripple R&D.
From my colleague Adam Feuerstein: Biogen and Stoke Therapeutics have signed a partnership agreement to co-develop and sell ...
The biotech industry is on a stable growth path, owing to the integration of modern technologies and rapid drug discoveries.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback